Celldex Therapeutics (NASDAQ:CLDX) Price Target Lowered to $36.00 at The Goldman Sachs Group

Celldex Therapeutics (NASDAQ:CLDX) had its target price reduced by The Goldman Sachs Group from $42.00 to $36.00 in a research note issued to investors on Monday morning,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the stock. UBS Group initiated coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Friday. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $55.38.

Celldex Therapeutics Stock Down 5.9 %

CLDX opened at $19.35 on Monday. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -7.53 and a beta of 1.60. The firm has a 50-day moving average price of $23.75 and a 200-day moving average price of $28.80. Celldex Therapeutics has a twelve month low of $19.31 and a twelve month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. On average, sell-side analysts expect that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. KBC Group NV grew its stake in Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 495 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Celldex Therapeutics by 2.1% in the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company’s stock worth $1,064,000 after acquiring an additional 871 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 878 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Celldex Therapeutics by 1.2% in the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company’s stock worth $2,964,000 after acquiring an additional 1,400 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its holdings in shares of Celldex Therapeutics by 5.1% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock worth $1,449,000 after acquiring an additional 2,070 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.